|PETCM Caspase-3 activator|
Sample solution is provided at 25 µL, 10mM.
Publications citing ApexBio Products
|Cas No.||10129-56-3||SDF||Download SDF|
|Solubility||<12.03mg/ml in 1eq. HCl||Storage||Store at RT|
|Physical Appearance||Tan crystalline solid||Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
PETCM is an activator of caspase-3 .
Caspase-3 is a member of the cysteine-aspartic acid protease family and interacts with caspase-8 and caspase-9. Sequential activation of caspases plays an important role in cell apoptosis.
In HeLa S-100 cell cytosol, PETCM activated caspase-3 in a dose-dependent way and induced apoptosome formation. PETCM (0.2 mM) caused Apaf-1 shifted to a size of ~1 million daltons, which indicating apoptosome formation. Also, PETCM function required dATP. The activation effect of PETCM on caspase-3 was independent of PHAP proteins. When inhibited the activation activity of the PHAP proteins, PETCM reversed the suppression. When added to Q30 (Apaf-1/procaspase-9) plus cytochrome c and 10 μM dATP, recombinant PHAPI activated caspase-3. The activity was inhibited by recombinant ProT. While, PETCM reversed the inhibitory effect of ProT. PHAPI didn’t affect apoptosome formation and activated caspase-9 and Apaf-1, which were associated with apoptosome. ProT efficiently blocked formation of apoptosome and PETCM relieved this effect .
. Jiang X, Kim HE, Shu H, et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science, 2003, 299(5604): 223-226.